留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

赵全凤,  龚玉竹,  谢赣丰,  夏培元,  唐敏

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(6): 559-562
赵全凤, 龚玉竹, 谢赣丰, 夏培元, 唐敏. 临床药师参与晚期直肠神经内分泌瘤患者的药学服务[J]. 药学实践与服务, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
引用本文: 赵全凤, 龚玉竹, 谢赣丰, 夏培元, 唐敏. 临床药师参与晚期直肠神经内分泌瘤患者的药学服务[J]. 药学实践与服务, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
shu
ZHAO Quanfeng, GONG Yuzhu, XIE Gangfeng, XIA Peiyuan, TANG Min. Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
Citation: ZHAO Quanfeng, GONG Yuzhu, XIE Gangfeng, XIA Peiyuan, TANG Min. Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
shu

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017
  • 1.

    陆军军医大学第一附属医院药学部, 重庆 400038

  • 2.

    陆军军医大学第一附属医院肿瘤科, 重庆 400038

基金项目: 国家自然科学基金青年科学基金项目（81802117）

Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor

  • 1.

    Department of pharmacy, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

  • 2.

    Department of Oncology, Southwest Hospital, First Affiliated Hospital to Army Medical University, Chongqing 400038, China

  • 摘要: 目的 探讨临床药师在晚期直肠神经内分泌瘤患者抗肿瘤治疗中的作用。 方法 临床药师参与1例晚期直肠神经内分泌瘤患者的药学服务过程中，结合患者实际情况，从用药的有效性和安全性方面提供治疗方案建议，并进行全程药学监护。 结果 依维莫司可引起高血糖的严重不良反应，用药时需注意监测；阿帕替尼可作为晚期直肠神经内分泌瘤患者后线化疗的选择。 结论 新型抗肿瘤药物不良反应的监护和缺乏循证药学证据的情况下，后线如何选择抗肿瘤药物，是临床药师工作的切入点，此对提高晚期直肠神经内分泌瘤患者的用药安全性和有效性方面起着重要作用。
    Abstract: Objective To investigate the role of clinical pharmacists in anti-tumor therapy in patients with advanced rectal neuroendocrine tumors. Methods Clinical pharmacists participated in the pharmacy service of a patient with advanced rectal neuroendocrine tumor.Combined with the actual situation of the patient,the clinical pharmacist provided advice on the efficacy and safety of the medication and conducted full-course pharmaceutical care. Results Everolimus can cause serious adverse reactions of hyperglycemia and should be monitored when using drugs.Apatinib can be used as a choice for posterior chemotherapy in patients with advanced rectal neuroendocrine tumors. Conclusion In the case of monitoring the adverse effects of new anti-tumor drugs and lack of evidence-based pharmacological evidence,how to choose anti-tumor drugs in the posterior line is the entry point for clinical pharmacists' work,which plays an important role for improving the safety and efficacy of the drug use of patients with advanced rectal neuroendocrine tumors.
  • [1] 徐建明,梁后杰,秦叔逵,等.中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J].临床肿瘤学杂志,2016,21(10):927-946.
    [2] DASARI A,SHEN C,HALPERIN D,et al.Trends in the incidence,prevalence,and survival outcomes in patients withneuroendocrine tumors in the United States[J].JAMA Oncol,2017,3(10):1335-1342.
    [3] U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES,Common Terminology Criteria for Adverse Events (CTCAE) v5.0.November 27,2017.
    [4] MORVIDUCCI L,ROTA F,RIZZA L,et al.Everolimus is a new anti-cancer molecule:Metabolic side effects as lipid disorders and hyperglycemia[J].Diabetes Res Clin Pract,2018,143:428-431.
    [5] FAZIO N,BUZZONI R,DELLE FAVE G,et al.Everolimus in advanced,progressive,well-differentiated,non-functional neuroendocrine tumors:RADIANT-4 lung subgroup analysis[J].Cancer Sci,2018,109(1):174-181.
    [6] LIU C T,CHEN M H,CHEN J S,et al.The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors:a multi-institution observational study in Taiwan[J].Asia Pac J Clin Oncol,2016,12(4):396-402.
    [7] GUO Z H,JIAO YY,YI Z M,et al.Increased risk of hyperglycemia associated with the use of everolimus in patients with cancer:a systematic review and Meta-analysis[J].J Chin Pharm Sci,2015,24(5):326-335.
    [8] 依维莫司临床安全性管理专家小组.依维莫司临床安全性管理专家意见[J].中国新药杂志,2014,23(22):2694-2700.
    [9] KUNZ P L,KUO T,ZAHN J M,et al.A phase II study ofcapecitabine,oxaliplatin,and bevacizumab for metastatic or unresectable neuroendocrine tumors[J].J Clin Oncol,2010,28(15_suppl):4104.
    [10] YAO J C,GUTHRIE K A,MORAN C,et al.Phase III prospective randomized comparison trial of depotoctreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors:SWOG S0518[J].J Clin Oncol,2017,35(15):1695-1703.
    [11] FAIVRE S,NICCOLI P,CASTELLANO D,et al.Sunitinib in pancreatic neuroendocrine tumors:updated progression-free survival and final overall survival from a phase III randomized study[J].Ann Oncol,2017,28(2):339-343.
    [12] CASTELLANO D,CAPDEVILA J,SASTRE J,et al.Sora-fenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour:a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)[J].Eur J Cancer,2013,49(18):3780-3787.
    [13] GRANDE E,CAPDEVILA J,CASTELLANO D,et al.Pazopanib in pretreated advanced neuroendocrine tumors:a phase II,open-label trial of the Spanish task force group for neuroendocrine tumors (GETNE)[J].Ann Oncol,2015,26(9):1987-1993.
    [14] CHEN C,GONG X L,LIAO F,et al.A real world study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients[J].J Clin Oncol,2018,36(15_suppl):e14567.
  • [1] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [2] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [3] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [4] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [5] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3282
  • HTML全文浏览量:  481
  • PDF下载量:  899
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-05-08
  • 修回日期:  2019-10-28

临床药师参与晚期直肠神经内分泌瘤患者的药学服务

doi: 10.3969/j.issn.1006-0111.2019.06.017
  • 1. 陆军军医大学第一附属医院药学部, 重庆 400038
  • 2. 陆军军医大学第一附属医院肿瘤科, 重庆 400038
    • 基金项目:  国家自然科学基金青年科学基金项目（81802117）
  • 收稿日期: 2019-05-08
  • 修回日期: 2019-10-28

摘要: 目的 探讨临床药师在晚期直肠神经内分泌瘤患者抗肿瘤治疗中的作用。 方法 临床药师参与1例晚期直肠神经内分泌瘤患者的药学服务过程中，结合患者实际情况，从用药的有效性和安全性方面提供治疗方案建议，并进行全程药学监护。 结果 依维莫司可引起高血糖的严重不良反应，用药时需注意监测；阿帕替尼可作为晚期直肠神经内分泌瘤患者后线化疗的选择。 结论 新型抗肿瘤药物不良反应的监护和缺乏循证药学证据的情况下，后线如何选择抗肿瘤药物，是临床药师工作的切入点，此对提高晚期直肠神经内分泌瘤患者的用药安全性和有效性方面起着重要作用。

English Abstract

赵全凤, 龚玉竹, 谢赣丰, 夏培元, 唐敏. 临床药师参与晚期直肠神经内分泌瘤患者的药学服务[J]. 药学实践与服务, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
引用本文: 赵全凤, 龚玉竹, 谢赣丰, 夏培元, 唐敏. 临床药师参与晚期直肠神经内分泌瘤患者的药学服务[J]. 药学实践与服务, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
shu
ZHAO Quanfeng, GONG Yuzhu, XIE Gangfeng, XIA Peiyuan, TANG Min. Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
Citation: ZHAO Quanfeng, GONG Yuzhu, XIE Gangfeng, XIA Peiyuan, TANG Min. Clinical pharmacists involved in the pharmaceutical care of patients with advanced rectal neuroendocrine tumor[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
shu

    全文HTML

参考文献 (14)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计